Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Structure-guided design of ultrapotent disruptive IgE inhibitors to rapidly terminate acute allergic reactions

Journal of Allergy and Clinical Immunology(2021)10.1016/j.jaci.2021.03.050Source: DataRank Database

Structure-guided design of ultrapotent disruptive IgE inhibitors to rapidly terminate acute allergic reactions is a research paper published in Journal of Allergy and Clinical Immunology (2021). On theSindex it has a DataRank of 0. It has been cited 39 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access39 citations

Download PDF

Cite:

Linked data & code

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (8 grants)Impact (FWCI 2.27)OA: greenTopics (55)Linked Datasets (2)DataCite Reuse (2)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (6)

P. Gasser ORCID,Daniel Brigger,Pascal Guntern ORCID,Alexander Eggel ORCID,Theodore S. Jardetzky ORCID

Live enrichment

PubMed:33991582 PMC:PMC8502201 OpenAlex:https://openalex.org/W3160824125

National Institutes of Health

Grant: AI115469

National Institutes of Health

Grant: HL141493

NIAID NIH HHS

Grant: R01 AI115469

NHLBI NIH HHS

Grant: R01 HL141493

NIAID NIH HHS

Grant: R21 AI166496

Fondation Acteria

Lungenliga Schweiz

Uniscientia Foundation

FWCI

2.27

Citation Percentile

0.9%

Citation Trend

2020

2021

2022

2023

2024

2025

2026

greenLicense: https://www.elsevier.com/legal/tdmrep-license

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8502201

publisherhttps://api.elsevier.com/content/article/PII:S0091674921007302?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0091674921007302?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.jaci.2021.03.050

Fields of Study

Mast cells and histamineMonoclonal and Polyclonal Antibodies ResearchFood Allergy and Anaphylaxis ResearchAllergensAnaphylaxisAnimalsBasophilsDrug DesignHumansImmunoglobulin EMice, TransgenicMolecular StructureOvalbuminReceptors, IgERecombinant Fusion Proteins

MeSH Terms

AllergensAnaphylaxisAnimalsBasophilsHumansImmunoglobulin EMice, TransgenicOvalbuminRecombinant Fusion ProteinsDrug DesignMolecular StructureReceptors, IgE

Keywords

Immunoglobulin EAnaphylaxisDesensitization (medicine)ImmunologyAllergyIn vivoEffectorMedicineBasophil activationAllergic responseMast cellIn vitroBasophilChemistryReceptorAntibodyBiologyInternal medicineBiochemistryYeast displayIgEAffinity maturationAllergiesDarpinsFc FusionActive DesensitizationDisruptive Ige InhibitorsKnobs In Holes

Sustainable Development Goals

SDG 0: Good health and well-being

Additional file 1 of Safety of inactivated SARS-CoV-2 vaccines in patients with allergic diseases

10.6084/m9.figshare.19915416.v1figshare

Additional file 1 of Safety of inactivated SARS-CoV-2 vaccines in patients with allergic diseases

10.6084/m9.figshare.19915416figshare